Experience With Rapid Drug Desensitisation With Chemotherapeutics; A Single-Centre Retrospective Study
Murat Ayhan1, Kadriye Terzioglu21Department of Medical Oncology, Health Science University Kartal Dr. Lütfi Kirdar City Hospital, Istanbul, Turkey, 2Adult Immunology and Allergy Clinic, Health Science University Kartal Dr. Lütfi Kirdar City Hospital, Istanbul, Turkey Adult Immunology and Allergy Clinic, Health Science University Kartal Dr. Lütfi Kirdar City Hospital, Istanbul, Turkey
Objectives: Our aim is to share our platinum salt-, taxane- and irinotecan-induced rapid drug desensitisation (RDD) experiences. Methods: In our study, the demographic data, initial HSR grades, skin test results and RDD success rates of patients who underwent a 12-step RDD protocol, and their breakthrough reactions (BTR) observed during desensitisation were retrospectively examined. Results: The mean age of 28 patients who underwent RDD (platinum=22, taxane=4, irinotecan=2) was 57 (40-72), and 53.6% of the patients were female. 87 RDD procedures (platinum=56, taxane=21, irinotecan=10) were performed in total. 32.1% of the initial HSRs were grade 3 and 60.7% were grade 2. In terms of skin test results, 17 patients in the platinum group showed positivity to skin test. Two patients with negative results had a positive result on graded challenge. One patient in the taxane group had a negative skin test result yet had a grade 3 HSR. BTRs were observed in 46.4% of our patients – but none were at grade 3 in severity. 5 patients were unable to successfully complete the RDD protocol. Conclusion: 12-step protocol was proven safe and efficient in our experiences with RDD. Our RDD success rate was 94.3%. Keywords: Breakthrough reactions, chemotherapy, drug allergy, hypersensitivity reaction, rapid drug desensitisation
Cite This Article
Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitisation With Chemotherapeutics; A Single-Centre Retrospective Study. EJMI. 2021; 5(3): 380-387
Corresponding Author: Murat Ayhan